Drug
Enpatoran
Enpatoran: highest development phase Phase 3, developed by Merck KGaA. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Merck KGaA
Trials
| Drug | Phase | Indication |
|---|---|---|
| Enpatoran NCT07332481 | Phase 3 | Systemic Lupus Erythematosus (SLE) |
| Enpatoran NCT07355218 | Phase 3 | Systematic Lupus Erythematosus |
| Enpatoran NCT07840287 | Phase 3 | Systemic Lupus Erythematosus (SLE) |
Latest
No recent events.
Follow Enpatoran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.